Your browser doesn't support javascript.
loading
External Evaluation of a Mammography-based Deep Learning Model for Predicting Breast Cancer in an Ethnically Diverse Population.
Omoleye, Olasubomi J; Woodard, Anna E; Howard, Frederick M; Zhao, Fangyuan; Yoshimatsu, Toshio F; Zheng, Yonglan; Pearson, Alexander T; Levental, Maksim; Aribisala, Benjamin S; Kulkarni, Kirti; Karczmar, Gregory S; Olopade, Olufunmilayo I; Abe, Hiroyuki; Huo, Dezheng.
Afiliação
  • Omoleye OJ; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Woodard AE; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Howard FM; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Zhao F; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Yoshimatsu TF; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Zheng Y; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Pearson AT; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Levental M; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Aribisala BS; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Kulkarni K; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Karczmar GS; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Olopade OI; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Abe H; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
  • Huo D; From the Center for Clinical Cancer Genetics and Global Health, Department of Medicine (O.J.O., A.E.W., T.F.Y., Y.Z., B.S.A., O.I.O.), Data Science Institute (A.E.W.), Division of Hematology/Oncology, Department of Medicine (F.M.H., A.T.P.), Department of Public Health Sciences (F.Z., D.H.), Departm
Radiol Artif Intell ; 5(6): e220299, 2023 Nov.
Article em En | MEDLINE | ID: mdl-38074785
ABSTRACT

Purpose:

To externally evaluate a mammography-based deep learning (DL) model (Mirai) in a high-risk racially diverse population and compare its performance with other mammographic measures. Materials and

Methods:

A total of 6435 screening mammograms in 2096 female patients (median age, 56.4 years ± 11.2 [SD]) enrolled in a hospital-based case-control study from 2006 to 2020 were retrospectively evaluated. Pathologically confirmed breast cancer was the primary outcome. Mirai scores were the primary predictors. Breast density and Breast Imaging Reporting and Data System (BI-RADS) assessment categories were comparative predictors. Performance was evaluated using area under the receiver operating characteristic curve (AUC) and concordance index analyses.

Results:

Mirai achieved 1- and 5-year AUCs of 0.71 (95% CI 0.68, 0.74) and 0.65 (95% CI 0.64, 0.67), respectively. One-year AUCs for nondense versus dense breasts were 0.72 versus 0.58 (P = .10). There was no evidence of a difference in near-term discrimination performance between BI-RADS and Mirai (1-year AUC, 0.73 vs 0.68; P = .34). For longer-term prediction (2-5 years), Mirai outperformed BI-RADS assessment (5-year AUC, 0.63 vs 0.54; P < .001). Using only images of the unaffected breast reduced the discriminatory performance of the DL model (P < .001 at all time points), suggesting that its predictions are likely dependent on the detection of ipsilateral premalignant patterns.

Conclusion:

A mammography DL model showed good performance in a high-risk external dataset enriched for African American patients, benign breast disease, and BRCA mutation carriers, and study findings suggest that the model performance is likely driven by the detection of precancerous changes.Keywords Breast, Cancer, Computer Applications, Convolutional Neural Network, Deep Learning Algorithms, Informatics, Epidemiology, Machine Learning, Mammography, Oncology, Radiomics Supplemental material is available for this article. © RSNA, 2023See also commentary by Kontos and Kalpathy-Cramer in this issue.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Radiol Artif Intell Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Radiol Artif Intell Ano de publicação: 2023 Tipo de documento: Article